Patents by Inventor Burkhard Goeke

Burkhard Goeke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Exendin improves ?-cell response in subjects with impaired glucose tolerance
    Patent number: 7265087
    Abstract: A composition for the treatment of impaired glucose tolerance (IGT) including a compound which binds to a receptor for glucagon-like peptide-1, and a pharmaceutical carrier. The amount of the compound present is an effective amount to improve pancreatic ?-cell sensitivity to blood glucose levels in a human with IGT. Also, a method for improving the pattern of insulin secretory responses in a human with IGT by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: September 4, 2007
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Burkhard Göke, Maria Byrne, Thomas R. Coolidge
  • Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
    Publication number: 20030216292
    Abstract: The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.
    Type: Application
    Filed: June 9, 2003
    Publication date: November 20, 2003
    Inventors: Burkhard Goeke, Joerg Schirra
  • Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
    Patent number: 6579851
    Abstract: The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP1(7-36)amide slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: June 17, 2003
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Burkhard Goeke, Joerg Schirra
  • Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
    Publication number: 20020098195
    Abstract: The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.
    Type: Application
    Filed: March 14, 2001
    Publication date: July 25, 2002
    Inventors: Burkhard Goeke, Joerg Schirra